FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1275-1280 April 25, 2002 Number 17 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background We conducted a double-blind, randomized trial of three dilutions of vaccinia virus vaccine in previously unimmunized adults in order to assess the clinical success rates, humoral responses, and virus-specific activity of cytotoxic T cells and interferon-–producing T cells.

Methods Sixty healthy adults were inoculated intradermally by bifurcated needle with undiluted vaccine (dose, 10^7.8 plaque-forming units [pfu] per milliliter), a 1:10 dilution (dose, 10^6.5 pfu per milliliter), or a 1:100 dilution (dose, 10^5.0 pfu per milliliter); there were 20 subjects in each group. The subjects were monitored with respect to vesicle formation (an indicator of successful vaccination), the viral titer at the time of peak lesion formation, antiviral antibodies, and cellular immune responses.

Results A vaccinia vesicle developed in 19 of the 20 subjects who received undiluted vaccine (95 percent), 14 of the 20 who received the 1:10 dilution (70 percent), and 3 of the 20 who received the 1:100 dilution (15 percent). One month after vaccination, 34 of 36 subjects with vesicles had antibody responses, as compared with only 1 of 24 subjects without clinical evidence of vaccinia virus replication. Vigorous cytotoxic T-cell and interferon- responses occurred in 94 percent of subjects with vesicles, and a cytotoxic T-cell response occurred in only one subject without a vesicle.

Conclusions The vaccinia virus vaccine (which was produced in 1982 or earlier) still has substantial potency when administered by a bifurcated needle to previously unvaccinated adults. Diluting the vaccine reduces the rate of successful vaccination. The development of vesicular skin lesions after vaccination correlates with the induction of the antibody and T-cell responses that are considered essential for clearing vaccinia virus infections.

Source Information

From the Department of Medicine, National Institute of Allergy and Infectious Diseases Vaccine and Treatment Evaluation Unit, Saint Louis University School of Medicine, St. Louis (S.E.F., F.K.N., W.B.S., J.M.T., T.P., R.B.B.); the Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester (J.C., A.L.R., J.S.K., F.A.E); and the Emmes Corporation, Rockville, Md. (M.W.).

This article was published at www.nejm.org on March 28, 2002.

Address reprint requests to Dr. Frey at the Division of Infectious Diseases and Immunology, Saint Louis University Health Sciences Center, 3635 Vista Ave. (FDT-8N), St. Louis, MO 63110.

Full Text of this Article

Related Letters:

Responses to Smallpox Vaccine
Sauri M. A., Frelinger J. A., Garba M. L., Belshe R. B., Frey S. E.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:689-690, Aug 29, 2002. Correspondence

This article has been cited by other articles:

• Precopio, M. L., Betts, M. R., Parrino, J., Price, D. A., Gostick, E., Ambrozak, D. R., Asher, T. E., Douek, D. C., Harari, A., Pantaleo, G., Bailer, R., Graham, B. S., Roederer, M., Koup, R. A. (2007). Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. J. Exp. Med. 204: 1405-1416 [Abstract] [Full Text]  
• Nakajima, K., Dharmage, S. C, Carlin, J. B, Wharton, C. L, Jenkins, M. A, Giles, G. G, Abramson, M. J, Haydn Walters, E, Hopper, J. L (2007). Is childhood immunisation associated with atopic disease from age 7 to 32 years?. Thorax 62: 270-275 [Abstract] [Full Text]  
• Kim, S.-H., Yeo, S.-G., Cho, J.-H., Kim, H.-B., Kim, N.-J., Oh, M.-d., Choe, K.-W., Jee, Y., Cho, H. (2006). Cell-Mediated Immune Responses to Smallpox Vaccination. CVI 13: 1172-1174 [Abstract] [Full Text]  
• Monath, T. P., Liu, J., Kanesa-Thasan, N., Myers, G. A., Nichols, R., Deary, A., McCarthy, K., Johnson, C., Ermak, T., Shin, S., Arroyo, J., Guirakhoo, F., Kennedy, J. S., Ennis, F. A., Green, S., Bedford, P. (2006). A live, attenuated recombinant West Nile virus vaccine. Proc. Natl. Acad. Sci. USA 103: 6694-6699 [Abstract] [Full Text]  
• Smith, C. L., Mirza, F., Pasquetto, V., Tscharke, D. C., Palmowski, M. J., Dunbar, P. R., Sette, A., Harris, A. L., Cerundolo, V. (2005). Immunodominance of Poxviral-Specific CTL in a Human Trial of Recombinant-Modified Vaccinia Ankara. J. Immunol. 175: 8431-8437 [Abstract] [Full Text]  
• Davies, D. H., McCausland, M. M., Valdez, C., Huynh, D., Hernandez, J. E., Mu, Y., Hirst, S., Villarreal, L., Felgner, P. L., Crotty, S. (2005). Vaccinia Virus H3L Envelope Protein Is a Major Target of Neutralizing Antibodies in Humans and Elicits Protection against Lethal Challenge in Mice. J. Virol. 79: 11724-11733 [Abstract] [Full Text]  
• Kelso, J. M., Kuhn, K. M., Newman, F. K., Kennedy, J. S., Frey, S. E. (2005). Immune Status in a Primary Smallpox Vaccinee Who Failed to Develop an Immunization Site Reaction. JAMA 293: 677-678 [Full Text]  
• Kaufman, H. L. (2005). Integrating Bench With Bedside: The Role of Vaccine Therapy in the Treatment of Solid Tumors. JCO 23: 659-661 [Full Text]  
• McCurdy, L. H., Rutigliano, J. A., Johnson, T. R., Chen, M., Graham, B. S. (2004). Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4. J. Virol. 78: 12471-12479 [Abstract] [Full Text]  
• Jefferson, T. (2004). Bioterrorism and compulsory vaccination. BMJ 329: 524-525 [Full Text]  
• Tenorio, A. R., Peeples, M. E., Patri, M., Rezai, K., Trenholme, G. M. (2004). Evolution of Vaccinia Virus-Specific CD8+ Cytotoxic T-Lymphocyte Responses in Primary Vaccinees and Revaccinees. CVI 11: 758-761 [Abstract] [Full Text]  
• Combadiere, B., Boissonnas, A., Carcelain, G., Lefranc, E., Samri, A., Bricaire, F., Debre, P., Autran, B. (2004). Distinct Time Effects of Vaccination on Long-Term Proliferative and IFN-{gamma}-producing T Cell Memory to Smallpox in Humans. J. Exp. Med. 199: 1585-1593 [Abstract] [Full Text]  
• Neyts, J., Leyssen, P., Verbeken, E., De Clercq, E. (2004). Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia. Antimicrob. Agents Chemother. 48: 2267-2273 [Abstract] [Full Text]  
• Amara, R. R., Nigam, P., Sharma, S., Liu, J., Bostik, V. (2004). Long-Lived Poxvirus Immunity, Robust CD4 Help, and Better Persistence of CD4 than CD8 T Cells. J. Virol. 78: 3811-3816 [Abstract] [Full Text]  
• Crotty, S., Felgner, P., Davies, H., Glidewell, J., Villarreal, L., Ahmed, R. (2003). Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination. J. Immunol. 171: 4969-4973 [Abstract] [Full Text]  
• Karanikas, V., Lurquin, C., Colau, D., van Baren, N., De Smet, C., Lethe, B., Connerotte, T., Corbiere, V., Demoitie, M.-A., Lienard, D., Dreno, B., Velu, T., Boon, T., Coulie, P. G. (2003). Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus. J. Immunol. 171: 4898-4904 [Abstract] [Full Text]  
• Belyakov, I. M., Earl, P., Dzutsev, A., Kuznetsov, V. A., Lemon, M., Wyatt, L. S., Snyder, J. T., Ahlers, J. D., Franchini, G., Moss, B., Berzofsky, J. A. (2003). Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100: 9458-9463 [Abstract] [Full Text]  
• Newman, F. K., Frey, S. E., Blevins, T. P., Mandava, M., Bonifacio, A. Jr., Yan, L., Belshe, R. B. (2003). Improved Assay To Detect Neutralizing Antibody following Vaccination with Diluted or Undiluted Vaccinia (Dryvax) Vaccine. J. Clin. Microbiol. 41: 3154-3157 [Abstract] [Full Text]  
• Frey, S. E., Newman, F. K., Yan, L., Belshe, R. B. (2003). Response to Smallpox Vaccine in Persons Immunized in the Distant Past. JAMA 289: 3295-3299 [Abstract] [Full Text]  
• Terajima, M., Cruz, J., Raines, G., Kilpatrick, E. D., Kennedy, J. S., Rothman, A. L., Ennis, F. A. (2003). Quantitation of CD8+ T Cell Responses to Newly Identified HLA-A*0201-restricted T Cell Epitopes Conserved Among Vaccinia and Variola (Smallpox) Viruses. J. Exp. Med. 197: 927-932 [Abstract] [Full Text]  
• Veenema, T. G. (2003). Safeguarding Our Nation's Children: The Diagnosis, Management, and Containment of Smallpox in Infants and Children. Biol Res Nurs 4: 295-304 [Abstract]  
• Belongia, E. A., Naleway, A. L. (2003). Smallpox Vaccine: The Good, the Bad, and the Ugly. Clin Med Res 1: 87-92 [Abstract] [Full Text]  
• Committee on Infectious Diseases, (2002). Smallpox Vaccine. Pediatrics 110: 841-845 [Abstract] [Full Text]  
• Sauri, M. A., Frelinger, J. A., Garba, M. L., Belshe, R. B., Frey, S. E. (2002). Responses to Smallpox Vaccine. NEJM 347: 689-690 [Full Text]  
• (2002). Efficacy and Safety of Resurrected and Diluted Smallpox Vaccine. JWatch Infect. Diseases 2002: 1-1 [Full Text]  
• Frey, S. E., Couch, R. B., Tacket, C. O., Treanor, J. J., Wolff, M., Newman, F. K., Atmar, R. L., Edelman, R., Nolan, C. M., Belshe, R. B., the National Institute of Allergy and Infectious D, (2002). Clinical Responses to Undiluted and Diluted Smallpox Vaccine. NEJM 346: 1265-1274 [Abstract] [Full Text]  
• Breman, J. G., Henderson, D.A. (2002). Diagnosis and Management of Smallpox. NEJM 346: 1300-1308 [Full Text]  
• Frey, S. E., Couch, R. B., Tacket, C. O., Treanor, J. J., Wolff, M., Newman, F. K., Atmar, R. L., Edelman, R., Nolan, C. M., Belshe, R. B., the National Institute of Allergy and Infectious D, (2002). Clinical Responses to Undiluted and Diluted Smallpox Vaccine. NEJM 346: 1265-1274 [Abstract] [Full Text]  
• Breman, J. G., Henderson, D.A. (2002). Diagnosis and Management of Smallpox. NEJM 346: 1300-1308 [Full Text]